Compare Peloton Interactive Inc (PTON) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Peloton Interactive Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Peloton Interactive Inc trades at $5.04 (market cap $2.30B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 3.3× Peloton Interactive Inc's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Peloton Interactive Inc for 37 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PTON | SYRE | |
|---|---|---|
Market Cap | $2.30B | $7.52B |
Volume | 9,511,173 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.86 | $108.92 |
52-Week Low | $3.71 | $22.18 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $2.80B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Peloton (PTON) trades at $5.06, down 1.56% today, showing mixed technical signals with a bullish overall rating but bearish moving averages. The company achieved its first profitable year in 2026 with $63M net income, though Q3 2026 earnings are pending. Revenue declined from $3.6B in 2022 to $2.4B in 2026, but profitability improved significantly with net margin turning positive. Recent product launches include new treadmills and AI features, signaling ongoing turnaround efforts.
PTON presents a speculative opportunity with analyst consensus price target of $8.00 (58% upside) and 50% buy ratings. Key risks include declining subscriber counts, high debt levels, and competitive pressures. The stock's valuation appears reasonable with P/S of 0.93, but negative shareholder equity and volatile cash flow history warrant caution. Near-term catalyst will be Q3 2026 earnings results versus expectations of $0.1098 EPS.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
